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[percutaneous coronary intervention (PCI) vs coronary 
artery bypass grafting (CABG)] in the management of 
chronic stable angina.
Major changes in the revascularization strategies of 
symptomatic obstructive CAD have been seen in the past 
decade with a substantial shift toward PCI. It is always a 
matter of heated discussion as to which revascularization 
strategy is better. Although both the strategies have their 
merits, they are complementary to each other and should 
not replace one another. In Table 1, the relative advantages 
of both the strategies have been summarized.
AMERICAN COLLEGE OF CARDIOLOGY/
AMERICAN HEART ASSOCIATION 
REVASCULARIZATION GUIDELINES
We have summarized the recommendations from the 
Coronary artery disease (CAD) remains a major global 
public health problem. Chronic stable angina is a clinical 
expression of myocardial ischemia associated with ﬁ  xed 
atherosclerotic coronary stenosis, which prevents the 
adaptation of coronary circulation to an increased oxygen 
requirement. It is more common in men than in women 
and its prevalence increases sharply with age. About one 
half of patients presenting at the hospital with myocardial 
infarction (MI) have preceding angina.[1] On this basis, it 
has been estimated that there are 30 patients with a stable 
angina for every patient with infarction who is hospitalized. 
The annual[2,3] rate of MI is 3–3.5% and the annual mortality 
is 2–3%.
The goals of treatment include relief of symptoms, 
inhibition or slowing of disease progression, prevention of 
future cardiac events, such as MI, and improved survival. 
Here we focus on the role of revascularization strategies 
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ABSTRACT
Chronic stable angina is a clinical expression of myocardial ischemia associated with ﬁ  xed atherosclerotic 
coronary stenosis, which prevents the adaptation of coronary circulation resulting in an increased oxygen 
requirement. We recommend that once the diagnosis of chronic stable angina is made, ﬁ  rst every patient 
should be offered the optimal medical therapy, including ACE inhibitors, beta-blockers, statins, and nitrates. 
If the patients’ symptoms are not controlled in spite of these drugs being used in maximum tolerated dosages, 
then these patients should be subjected to coronary angiography. If a patient shows a single- or double-vessel 
disease, then PCI should be offered. On the contrary, if the coronary angiogram shows a triple-vessel disease 
and left main disease, then one has to look for comorbidities that put the patient at a higher risk of CABG and 
the patient should be treated with PCI. Other patients with left main and triple-vessel disease having diabetes 
and left ventricular dysfunction should go directly for surgical revascularization. Overall, health related quality 
of life ( HRQoL) is similar in both PCI and CABG.
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Table 1: Advantages and disadvantages of PCI vs CABG
PCI CABG
Age Preferred in very old and very young age  Avoided in extremes of age 
Comorbidities  PCI preferred in 
-Acute coronary syndrome
-Severe pulmonary diseases
-Dementia
-High stroke risk 
CABG is preferred in
Diabetes
Left ventricular systolic dysfunction
History of bleeding
Aspirin/clopidogrel allergy
Anatomical consideration PCI treats focal lesion 
Preferred in low syntax scores
CABG replaces whole artery and hence offers 
complete revascularization
Preferred in high syntax scores
Patients preference/clinical factors Less invasive
No scar mark
Shorter hospitalization
Early work resumption
Easily repeatable
More chances of recurrence of angina
More invasive
Scar mark
Longer hospitalization
Late work resumption
Redo CABG carries high mortality/morbidity
Less chances of recurrence of angina 
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting
Table 2: ACC/AHA 2007 revascularization guidelines[5]
PCI CABG
1- or 2-Vessel disease with mild or 
no symptoms, mild or no ischemia 
on noninvasive testing, and not yet 
receiving adequate medical therapy
III III
1- or 2-Vessel disease with moderate 
area at risk and ischemia on 
noninvasive testing
IIA IIA
1- or 2-Vessel disease with a 
large area at risk, noninvasive test 
indicating high risk, or failure of 
medical therapy
II
3-Vessel disease or 2-vessel disease 
+ pLAD, without diabetes mellitus or 
congestive heart failure
II
3-Vessel disease or 2-vessel Disease 
+ pLAD, and diabetes mellitus or 
congestive heart failure
IIB I
LM stenosis > 50% in a candidate for 
CABG
III I
LM stenosis > 50% in a noncandidate 
for CABG
IIB N/A
LM, ; pLAD; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass grafting
American College of Cardiology/American Heart 
Association (ACC/AHA, 2002) practice guidelines for 
chronic stable angina,[4] which were unchanged in the 2007 
update[5] and generally similar to those from the unstable 
angina/non–ST-elevation MI guidelines[6] from 2007 and 
have been summarized in Table 2.
MEDICAL THERAPY VS PERCUTANEOUS 
CORONARY INTERVENTION
PCIs are being increasingly used in patients with various 
manifestations of CAD. They represent an established 
treatment strategy that improves survival and survival free 
of recurrent MI in patients with ST-segment elevation MI. 
Early invasive therapy also improves long-term survival and 
reduces late MI in patients with non–ST-segment elevation 
MI. Although PCI reduces symptoms in patients without 
acute coronary syndromes, its effects on the prognosis of 
these patients are still not deﬁ  ned. The assessment of this 
issue has been difﬁ  cult for at least 2 reasons. First, patients 
with a stable CAD have a very good prognosis and large 
sample size studies are required to assess the potential 
differences in treatments in the case of rare events. All 
studies performed till date were far from having sufﬁ  cient 
power to assess mortality, and also, there is a certain risk 
associated with PCI, which leads to the aggregation of 
events in a relatively short period after the procedure. 
Any potential beneﬁ  cial effect of PCI compared with 
medical treatment alone may require time to offset this 
early aggregation of adverse events. 
In Courage Trial, 2287 patients who had an objective 
evidence of myocardial ischemia and signiﬁ  cant CAD were 
randomized to PCI with optimal medical therapy.[7] The 4.6-
year cumulative primary-event rates were 19.0% in the PCI 
group and 18.5% in the medical therapy group (hazard ratio 
for the PCI group, 1.05; 95% conﬁ  dence interval [CI], 0.87–
1.27; P = 0.62). There were 211 primary events in the PCI 
group and 202 events in the medical therapy group. There 
were no signiﬁ  cant differences between the PCI group and 
the medical therapy group in the composite of death, MI, 
and stroke (20.0% vs 19.5%; hazard ratio, 1.05; 95% CI, 
0.87–1.27; P = 0.62); hospitalization for acute coronary 
syndrome (12.4% vs 11.8%; hazard ratio, 1.07; 95% CI, 
0.84–1.37; P = 0.56); or MI (13.2% vs 12.3%; hazard ratio, J Cardiovasc. Dis. Res. Vol. 1 / No 2 56 Available Online: www.jcdronline.org
1.13; 95% CI, 0.89–1.43; P = 0.33). The authors of Courage 
Trial have concluded that, as an initial management strategy 
in patients with stable CAD, PCI did not reduce the risk 
of death, MI, or other major cardiovascular events when 
added to optimal medical therapy. 
Recently, a meta-analysis of 17 trials, including the Courage 
Trial by Schömig et al. [8] have shown that in chronic stable 
angina patients, the PCI strategy in comparison with that 
of the medical treatment group, leads to a 20% reduction 
in the odds ratio (OR) of all-cause death (OR: 0.80; 95% 
CI: 0.64–0.99, P = 0.263 for heterogeneity across the 
trials). Allocation to the PCI group was associated with a 
nonsigniﬁ  cant 26% reduction in the OR of cardiac death 
(OR: 0.74, 95% CI: 0.51–1.06). In the PCI group, 319 
patients had a nonfatal MI after randomization compared 
with 357 patients in the medical treatment group (OR: 
0.90, 95% CI: 0.66–1.23). Findings from this meta-analysis 
suggest that a PCI-based invasive strategy may improve 
long-term survival compared with a medical treatment-only 
strategy in patients with stable CAD.
PERCUTANEOUS CORONARY INTERVENTION VS 
CORONARY ARTERY BYPASS GRAFTING
A number of large randomized trials in the 1990s directly 
compared CABG with PCI. Their major ﬁ  nding was that 
survival was similar for the 2 modes of management, 
although PCI was associated with more repeated 
interventions.
One important exception was that patients with insulin-
requiring diabetes had a signiﬁ  cantly higher 5-year survival 
rate after CABG than after PCI (BARI Trial).[9]
Meta-analysis[10] of trials conducted before 1995, when 
coronary stenting was rare, revealed no significant 
differences in the treatment strategies for either death or the 
combined endpoint of death and MI. Mortality during the 
initial hospitalization for the procedure occurred in 1.3% 
of the CABG group and 1% of the PCI group. The need 
for subsequent revascularization was signiﬁ  cantly higher 
in the PCI group, and although patients were signiﬁ  cantly 
less likely to have angina 1 year after the bypass surgery 
than after PCI, by 3 years this difference was no longer 
statistically signiﬁ  cant. Results from the BARI study, the 
largest single randomized trial of PCI vs surgery, not 
included in this meta-analysis, were nonetheless consistent 
with these ﬁ  ndings, although a survival advantage with 
bypass surgery was observed in the diabetics.
It should be noted that similar to comparisons of PCI 
and pharmacotherapy, the early trials did not use stents 
or internal mammary artery grafts. These limitations 
were overcome in the ARTS I and SoS randomized trials 
comparing CABG with mostly arterial grafts to PCI with 
stent implantations. The ARTS I Trial[11] compared the 
strategy of multiple-stent implantation with the aim of 
complete revascularization vs bypass surgery in patients 
with multivessel disease. However, this trial was not carried 
out exclusively among patients with stable angina; 37% and 
35%, respectively, in both arms, had unstable angina, 57% 
and 60%, respectively, had stable angina, and 6% and 5%, 
respectively, had silent ischemia. As in the previous analyses 
of balloon angioplasty, at 1 year, there was no difference 
between the 2 groups in terms of rate of death, stroke, or 
MI. Among patients who survived without stroke or MI, 
16.8% of those in the stenting group underwent a second 
revascularization, when compared with 3.5% of those in 
the surgery group. The rate of event-free survival at 1 
year was 73.8% among the patients who received stents 
and 87.8% among those who underwent bypass surgery. 
As measured 1 year after the procedure, coronary stenting 
for multivessel disease in selected patients offered a similar 
outcome in terms of death, stroke, and MI as bypass 
surgery. However, stenting was associated with a greater 
need for repeated revascularization.
The ARTS II registry[12] indicated that the solution to 
revascularization may lie in the use of drug-eluting stents. 
The rate of major adverse cardiac and cerebrovascular 
events in this study was similar to that of the CABG 
arm in the ARTS I Trial and signiﬁ  cantly lower than that 
of the PCI with bare metal stent arm. After adjusting 
for risk factors, the authors noted a lower rate of major 
cardiovascular and cerebrovascular events in the PCI arm 
of ARTS II than in the CABG arm of ARTS I. However, 
the treatment assignment was not random. Most of 
the patients included in these randomized trials were 
relatively at low risk—fewer than 20% had left ventricular 
dysfunction and almost 70% had 1- or 2-vessel disease—
and therefore, were compatible with the patient group from 
whom CABG had not been found to be superior to PCI 
therapy. CABG has an advantage over PCI, which does not 
detect unstable plaques or the lesions most likely to be the 
cause of subsequent cardiac events. 
A meta-analysis by Hoffman et al., including trials of 
stents,[13] suggests a mortality beneﬁ  t with CABG compared 
with PCI at 5 years, which continued up to 8 years in 
patients with multivessel disease, as well as signiﬁ  cantly 
less angina and less need for a repeat revascularization. 
However, observational data with a 3-year follow-up on 
60,000 patients from the New York Cardiac Registry[14] 
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indicated that for patients with 2 or more diseased coronary 
arteries, CABG was associated with higher adjusted rates 
of long-term survival than stenting.
A meta-analysis by Bravata et al.[15] in 2007, which included 
23 RCTs in which 5019 patients were randomly assigned to 
PCI (POBA and BMS) and 4944 patients were randomly 
assigned to CABG showed that CABG was superior to PCI 
in relieving angina and averting repeat revascularization 
procedures. The rates of survival at 1, 5, and 10 years were 
similar for both the procedures, even though CABG carried 
a higher risk of stroke (1.2% vs 0.6% with PCI). However, 
most of the 23 studies did not involve patients with severe 
CAD (ie, left main or 3-vessel CAD). A limitation of this 
meta-analysis is that the author did not assess how the 
comparative outcomes vary according to clinical factors, 
such as the extent of coronary disease, ejection fraction, 
or previous procedures, and a majority of the patients 
randomized in the meta-analysis were not subjected to the 
latest revascularization technique.
Furthermore, PCI carries a risk for subacute and late-stent 
thrombosis and a need for prolonged antiaggregation 
treatment. A recent trial comparing PCI with CABG in 
patients with multivessel disease (ERACI–III) reported a 
higher rate of stent thrombosis (3.1% in 18 months). These 
data indicate that both the revascularization techniques are 
appropriate and comparable in outcome, except in patients 
with left main, 3-vessel disease, and in diabetics  for whom 
CABG is currently preferred.[16]
Similar to this, in a more recent meta-analysis by Daeman et 
al.[17] of 4 randomized trials (ARTS, ERACIII, MASS-II, and 
SoS Trials), PCI with stenting was associated with a long-
term safety proﬁ  le similar to that of CABG in multivessel 
CAD. However, as a result of persistently lower repeat 
revascularization rates in the CABG patients, the overall 
major adverse cardiac and cerebrovascular event rates were 
signiﬁ  cantly lower in the CABG group at 5 years.
Recently, the result of the Synergy between PCI with Taxus 
and Cardiac Surgery (SYNTAX) Trial,[18] in which 1800 
patients with left main or 3-vessel CAD were randomly 
assigned to undergo CABG or PCI (with drug-eluting stents) 
to determine which was the better revascularization strategy.
In the SYNTAX Trial, patients treated with PCI involving 
drug-eluting stents were more likely than those undergoing 
CABG to reach the primary endpoint of the study—death 
from any cause, stroke, MI, or repeat revascularization—
within 12 months after randomization (17.8% of patients 
vs 12.4%). In an analysis of secondary endpoints, the 2 
treatment groups had similar rates of death from any cause, 
stroke, or MI (7.6% for PCI and 7.7% for CABG). Patients 
undergoing PCI were more likely than those undergoing 
CABG to require repeat revascularization (13.5% vs 5.9%) 
but were less likely to have a stroke (0.6% vs 2.2%). This 
trial did not directly compare  both the strategies in all 
the chronic stable angina patients as  it was only anatomy 
guided. But even in a high-risk anatomy group, patients 
with serious coexisting conditions or vessels unsuitable 
for grafting (about 5% of patients in the SYNTAX 
study) are poor candidates for CABG, and they should 
be encouraged to undergo PCI. If safe and complete 
revascularization is possible with either PCI or CABG as it 
was in approximately 60% of the patients in the SYNTAX 
study, an assessment of coronary anatomy should be 
performed and a SYNTAX score assigned.[19] The presence 
of complex coronary anatomical features (indicated by a 
high SYNTAX score) identiﬁ  es patients with an increased 
risk of a suboptimal outcome with PCI; and they should be 
encouraged to undergo CABG.[20] Conversely, patients with 
less complex coronary anatomy (ie, a low SYNTAX score) 
should be presented with the advantages and disadvantages 
of each procedure and allowed to choose between them.[21]
Recently, in a nonrandomized study, including 240 patients 
in CABG group and 229 patients in PCI group, the health-
related quality of life (HRQoL) and the change in the 
NYHA class after CABG or PCI in the management of 
stable CAD have been assessed.[22] A three-year survival in 
both the groups was similar; HRQoL improved statistically 
in both the groups until 6 months after treatment but 
deteriorated toward the end of the follow-up of 36 
months. Clinically evident improvement of the HRQoL 
and decrease of the NYHA class took place more 
frequently among the CABG patients. Despite the initially 
more serious preoperative morbidity, the CABG patients 
achieved an equal level of HRQoL when compared with 
the PCI patients. The CABG patients might also obtain 
better relief from symptoms in the mid-term follow-up.
Coronary artery disease remains a major global public 
health problem. Chronic stable angina is a clinical 
expression of myocardial ischemia associated with 
ﬁ  xed atherosclerotic coronary stenosis, which prevents 
the adaptation of coronary circulation resulting in an 
increased oxygen requirement. As per the data available 
today, we recommend that once the diagnosis of chronic 
stable angina is made, every patient should be offered the 
optimal medical therapy, including ACE inhibitors, beta-
blockers, statins, and nitrates. If the patients’ symptoms 
are not controlled in spite of these, then these patients 
should be subjected to coronary angiography. If a patient 
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shows a single- or double-vessel disease, then PCI should 
be offered. On the contrary, if the coronary angiogram 
shows a triple-vessel disease and left main disease, then 
one has to look for comorbidities that put the patient at a 
higher risk of CABG and the patient should be treated with 
PCI. Other patients with left main and triple-vessel disease 
having diabetes and left ventricular dysfunction should go 
directly for surgical revascularization. Otherwise, in the 
patients of left main and triple-vessel disease, SYNTAX 
score should be calculated; if it is high (60%), then they 
should directly proceed for surgical revascularization, if low 
(1/3 patients), then either of the strategy can be offered as 
the initial method of revascularization. Overall, HRQoL is 
similar in both PCI and CABG.
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